TrialEBioMedicine2022

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.

Zoltán Bánki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.